A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
A phase 1/2 trial of Venetoclax, Gilteritinib, Azacitidine in multiple myeloma, run by Sumitomo Pharma America, Inc., now recruiting.
Overview
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) is a phase 1/2 interventional study registered as NCT04988555 by Sumitomo Pharma America, Inc., with 606 participants planned, started 2022-02-28 and due to reach its primary completion in 2027-06-30. Interventions recorded: Enzomenib, azoles, Venetoclax, Gilteritinib, Azacitidine (AZA). Conditions listed: Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma, Myelodysplastic Syndromes. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia
Shares Gilteritinib, Azacitidine, Venetoclax.
- TrialA Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia
Shares Azacitidine, Venetoclax.
- TrialA Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
Shares Venetoclax, Multiple myeloma.
- Term7+3 induction chemotherapy
Shares Gilteritinib, Azacitidine, Venetoclax.
- TrialStudy of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Shares Azacitidine, Venetoclax.
- TrialStudy to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Shares Azacitidine, Venetoclax, Multiple myeloma.
- TrialAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
Shares Venetoclax, Multiple myeloma.
- TrialIMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
Shares Azacitidine, Venetoclax.